Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from IBB

2 Ways to Play the Big Pharma Patent Cliff

With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.

MarketBeat

The Best Biotech ETFs to Buy

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

Kiplinger

Biotech Sector May Flip to Market Leader by Year-End

As rate cuts loom and after years of lagging, the biotech sector is showing signs of life, with IBB outpacing the benchmark S&P 500 on the quarter.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Turkey issues arrest warrants for 22 in Istanbul municipality corruption probe

Turkish authorities issued arrest warrants for 22 people, targeting Istanbul's Metropolitan Municipality over alleged corruption. Mayor İmamoğlu denies wrongdoing.

Euronews

3 Healthcare ETFs for Defensive Investing

The healthcare sector is poised for strong growth, driven by aging populations, technological advancements, and increased service demand. Thus, to gain exposure to the healthcare sector, one could capitalize on iShares Biotechnology (IBB), SPDR S&P Health Care Equipment (XHE), and iShares U.S. Medical Devices (IHI). Read on….

StockNews.com

3 Healthcare ETFs for a Resilient Portfolio

With benefits like diversified exposure, resilience, and relatively stable growth, healthcare ETFs present impressive opportunities for investors. Therefore, it could be wise to buy solid healthcare ETFs like First Trust Health Care AlphaDEX (FXH), iShares Biotechnology (IBB), and iShares U.S. Medical Devices (IHI) to build a resilient portfolio. Read more.

StockNews.com

3 Biotech ETFs for Diversified Innovation Exposure

Biotech ETFs provide the perfect balance of high-growth potential and diversified risk, offering investors access to healthcare breakthroughs. Given this backdrop, you might consider three biotech ETFs: iShares Biotechnology ETF (IBB), SPDR S&P Biotech ETF (XBI), and First Trust NYSE Arca Biotechnology Index Fund (FBT). Keep reading….

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Healthcare ETFs to Buy for Defensive Growth

Healthcare ETFs are an ideal investment choice for investors as they provide favorable returns, diversification, and robust growth opportunities even during economic downturns. Therefore, it could be wise to consider robust healthcare ETFs like iShares Biotechnology ETF (IBB), Vanguard Health Care Index Fund ETF Shares (VHT), and The Health Care…

StockNews.com

Faisal Saeed Al Mutar: Peace In The Middle East Through Capitalism

The co-founder of Ideas Beyond Borders argues that there is "no better independence than economic independence."

Reason

3 Biotech ETFs for a Diversified Portfolio

The biotech industry is growing rapidly with solid advancements, and ETFs in this sector can offer great investment opportunities. Thus, it could be wise to invest in top biotech ETFs SPDR S&P Biotech ETF (XBI), VanEck Biotech ETF (BBH), and iShares Biotechnology ETF (IBB) for a diversified portfolio. Read on.

StockNews.com

Why This Biotech ETF May Be About to Break Out

There’s a chance shares of the iShares Biotechnology ETF (NASDAQ: IBB) may be about to break out. They are testing a resistance level. If they can get above it, a new uptrend may form.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Regeneron Pharmaceuticals

65 stories

Vertex Pharmaceuticals Incorporated

65 stories

Vertex Pharmaceuticals

59 stories

Top!

51 stories

Regeneron Pharmaceuticals Inc

45 stories

First Trust

39 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.